BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a report published on Thursday morning. The firm issued a sell rating on the medical technology company’s stock.

BIOLASE Stock Performance

BIOLASE stock opened at $0.01 on Thursday. The company has a 50-day simple moving average of $0.01 and a 200-day simple moving average of $0.01. The firm has a market capitalization of $347,432.80, a P/E ratio of 0.00 and a beta of 0.67. BIOLASE has a one year low of $0.02 and a one year high of $1.94.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.